Arca
Skip to content
Tools
Tools

Leishmaniasis

Drug research and approvals for leishmaniasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 17 studies of leishmaniasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 13 open orphan designations naming it.

  • Recruiting worldwide: 17
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 17 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 8

Phase 3 8

Phase 2 5

Phase 1 or earlier 6

How its trials ended

193 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 61 whose ending is known, 48% met their primary endpoint, 11% missed it and 41% stopped early.

  • Completed, result not reported9047%
  • Met its primary endpoint2915%
  • Ongoing2714%
  • Status unknown158%
  • Stopped: other or unclear105%
  • Missed its primary endpoint74%
  • Stopped: lack of efficacy74%
  • Stopped: enrollment or feasibility63%
  • Stopped: safety11%
  • Stopped: sponsor or business decision11%

FDA orphan designations

Approved first, then open designations, newest first
Mar 19, 2014ImpavidoTreatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania…Knight Therapeutics (USA)Approved
Aug 11, 1997AmBisomeTreatment of visceral leishmaniasis.Fujisawa USA, Inc.Approved
Mar 20, 2025Parasite-selective proteasome inhibitor with potent…Treatment of leishmaniasisNovartis Pharmaceuticals CorporationDesignated
Jan 23, 2024Imiquimod-Ferulic AcidTreatment of Cutaneous LeishmaniasisCelista Pharmaceuticals LLCDesignated
Jul 19, 2021(2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrol…Treatment of cutaneous leishmaniasis (Old World and New World)Bacoba AGDesignated
Feb 11, 2015ParomomycinTreatment of cutaneous leishmaniasis (Old World and New World)Appili Therapeutics Inc.Designated
Jan 10, 2014Enchochleate amphotericin BTreatment of visceral leishmaniasisMatinas BioPharma Nanotechnologies, IncDesignated
Oct 25, 2013OleylphosphocholineTreatment of leishmaniasisOblita Therapeutics bvbaDesignated
Jul 6, 2011CorifunginTreatment of visceral leishmaniasisSandler Center for Drug DiscoveryDesignated
Sep 15, 2010Amphotericin BTreatment of visceral leishmaniasis.iCo Therapeutics Inc.Designated
Jan 18, 2008Paromomycin sulfate/gentamicin sulfateTreatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)Appili Therapeutics Inc.Designated
Jun 16, 2006Sodium stibogluconateTreatment of cutaneous leishmaniasisVioQuest Pharmaceuticals, Inc.Designated
Mar 29, 2005AminosidineTreatment of visceral leishmaniasisThe Institute for One World HealthDesignated
Sep 9, 1994AminosidineTreatment of visceral leishmaniasis (kala-azar).Kanyok, Thomas P. Pharm.D.Designated
Dec 4, 1985Allopurinol riboside1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasisBurroughs Wellcome CompanyDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.